T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status

AJNR. American Journal of Neuroradiology
Julio Arevalo-PerezR Young

Abstract

Epidermal growth factor receptor variant III is a common mutation in glioblastoma, found in approximately 25% of tumors. Epidermal growth factor receptor variant III may accelerate angiogenesis in malignant gliomas. We correlated T1-weighted dynamic contrast-enhanced MR imaging perfusion parameters with epidermal growth factor receptor variant III status. Eighty-two consecutive patients with glioblastoma and known epidermal growth factor receptor variant III status who had dynamic contrast-enhanced MR imaging before surgery were evaluated. Volumes of interest were drawn around the entire enhancing tumor on contrast T1-weighted images and then were transferred onto coregistered dynamic contrast-enhanced MR imaging perfusion maps. Histogram analysis with normalization was performed to determine the relative mean, 75th percentile, and 90th percentile values for plasma volume and contrast transfer coefficient. A Wilcoxon rank sum test was applied to assess the relationship between baseline perfusion parameters and positive epidermal growth factor receptor variant III status. The receiver operating characteristic method was used to select the cutoffs of the dynamic contrast-enhanced MR imaging perfusion parameters. Increased relativ...Continue Reading

References

Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amy B HeimbergerKenneth Aldape
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Nov 12, 2005·The New England Journal of Medicine·Ingo K MellinghoffPaul S Mischel
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yue CaoLarry Junck
Sep 26, 2007·AJNR. American Journal of Neuroradiology·S K EllikaT Mikkelsen
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Mar 28, 2009·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hui K GanRodney B Luwor
Sep 10, 2009·Science Signaling·Paul H HuangForest M White
Dec 21, 2012·AJR. American Journal of Roentgenology·Marco EssigMeng Law
Oct 15, 2013·Cell·Cameron W BrennanUNKNOWN TCGA Research Network
May 8, 2014·Journal of Immunology Research·Linda W XuGordon Li
Sep 23, 2014·JAMA Neurology·Alissa A ThomasAntonio M Omuro

❮ Previous
Next ❯

Citations

May 19, 2017·Current Neurology and Neuroscience Reports·Katherine M Mullen, Raymond Y Huang
Dec 25, 2019·Journal of Neuro-oncology·Yoshie UmemuraRobert J Young
Jan 13, 2017·Topics in Magnetic Resonance Imaging : TMRI·Nabil ElshafeeyRivka R Colen
Aug 29, 2019·Journal of Magnetic Resonance Imaging : JMRI·Anahita Fathi KazerooniChristos Davatzikos
Oct 18, 2016·Current Opinion in Oncology·Antonella Castellano, Andrea Falini
Apr 22, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Spyridon BakasChristos Davatzikos
Nov 18, 2020·Pharmaceutics·Huilong Luo, Eric V Shusta
Jun 26, 2021·Pathology, Research and Practice·Seyed Hamed JafariMajid Nejati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.